酪酸梭菌治疗骨质疏松症的研究进展

The development of the treatment of osteoporosis with clostridium butyricum

骨质疏松症是以骨量减少,导致骨脆性增高及骨折危险性增加的一种全身性骨病。随着社会人口老龄化骨质疏松性骨折越来越多见,显著增加了老年人死亡率以及社会经济负担。炎性肠病患者存在骨质丢失现象,与骨质疏松的发生密切相关,临床上常用酪酸梭菌辅助治疗炎性肠病,因而酪酸梭菌对骨质的影响应引起关注。本文通过联系炎性肠病引发骨质疏松、酪酸梭菌治疗炎性肠病的相关作用机制,以初步探讨酪酸梭菌可能具有治疗骨质疏松症的作用。

Osteoporosis is a systemic bone disease that reduces bone mass and leads to increased bone fragility and increased risk of fracture. With the increasing number of osteoporotic fractures in the social population, the mortality of the elderly and the social and economic burden increased significantly. Bone loss in patients with inflammatory bowel disease is closely related to the occurrence of osteoporosis. In clinical practice, clostridium butyricum is commonly used in the treatment of inflammatory bowel disease. Therefore, the effect of clostridium butyricum on bone should be concerned. This article discusses the possible mechanism of clostridium butyricum in the treatment of osteoporosis by connecting with inflammatory bowel disease and osteoporosis, and the related mechanism of clostridium butyricum in the treatment of inflammatory bowel disease.